EP2124979A2 - Extraits de ciste - Google Patents

Extraits de ciste

Info

Publication number
EP2124979A2
EP2124979A2 EP08708284A EP08708284A EP2124979A2 EP 2124979 A2 EP2124979 A2 EP 2124979A2 EP 08708284 A EP08708284 A EP 08708284A EP 08708284 A EP08708284 A EP 08708284A EP 2124979 A2 EP2124979 A2 EP 2124979A2
Authority
EP
European Patent Office
Prior art keywords
cistus
extracts
nasal sprays
nasal
plants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08708284A
Other languages
German (de)
English (en)
Inventor
Detlef Schierstedt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Krewel Meuselbach GmbH
Original Assignee
Krewel Meuselbach GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krewel Meuselbach GmbH filed Critical Krewel Meuselbach GmbH
Publication of EP2124979A2 publication Critical patent/EP2124979A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Definitions

  • the present invention relates to the use of a nasal spray from cistus extracts for the prevention and / or treatment of viral and / or bacterial diseases of the oropharynx.
  • influenza is an infectious viral disease that spreads around the world in seasonal epidemics, with three types of viruses, A, B and C. B and C are restricted to humans, while type A extends over mammals and birds.
  • EP 1 837 029 A1 describes a nasal spray which essentially contains an extract of cistus plants.
  • the particle size should therefore be> 30 ⁇ m to prevent drugs from entering the lungs.
  • the optimal particle range is between 0.5 to 5 ⁇ m.
  • Antiviral drugs are effective in the prevention and treatment of viral disease.
  • the direct medical cure of a viral disease has not yet been successful.
  • an elderberry extract is known for its effect of possibly shortening the duration of influenza without, however, showing a significant preventive effect (Zakay-Rones, Z. Varsano, N., Zlotnik, M., Manor, O.; Regev Schlesinger, M.; Mumcuoglu, MJ. Aging Complement, Med., 1995, 1 (4), 361-9).
  • Cistus incanus is used in animal husbandry as a natural remedy and generally to enhance the health of the animals (Pieroni, A. Howard, P., Volpato, G., Santoro, RF Vet. Res. Commun. 2004, 28 (1), 55 -80).
  • Cistus incanus ssp. tauricus Traditionally used for the treatment of skin diseases (Petereit F., Kolodziej H., Nahrstedt A. Phytochemistry 1991, 30 (3), 981-985).
  • Cistus species contain, among others, flavanoids and proanthocyanidins (Petereit F., Kolodziej H., Nahrstedt A. Phytochemistry 1991, 30 (3), 981-985), which can function as antioxidants in the body (Attaguile, G.; Russo, A.; Campisi, A., Savoca, F.; Acquaviva, R.; Ragusa, N., Vanella, A. Cell Biol, Toxicol 2000, 16 (2), 83-90). Extracts of the leaves of Cistus incanus are antibacterial and antimycotic (Bouamama, N. et al., 1999, 54 (6), 731-3).
  • the object of the present invention is therefore to provide an agent for the prophylaxis and / or treatment of viral diseases, for example influenza and cold, which can be produced inexpensively and does not produce any side effects during administration.
  • viral diseases for example influenza and cold
  • This object is achieved by the use of extracts of plants or plant constituents of the genus Cistus for the preparation of a nasal spray for the prevention and / or treatment of viral and / or bacterial diseases of the nasopharynx and / or pharynx.
  • the invention thus in a first embodiment, nasal sprays from extracts of plants or plant constituents of the genus Cistus having a particle size of at least 30 microns for the prevention and / or treatment of viral and / or bacterial diseases of the nasopharynx and / or pharynx.
  • a Cistus nasal spray provides comparable prophylactic effects, but does not have the disadvantages described above.
  • the particle size of the nasal sprays according to the invention Due to the particle size of the nasal sprays according to the invention, these are not respirable but have a special effect in the oral, nasal and pharyngeal space, while aerosols with smaller particle sizes have little or no effect here.
  • the particle size desired according to the invention can be produced by commercially available atomizers and pump sprays.
  • sprays also include those containing antibiotics, vasoconstrictants, for example oxymetazoline or xylometazoline hydrochloride, which cause swelling of the nasal mucosa, for example in the case of colds, so that it is possible to breathe more freely through the nose.
  • antibiotics for example oxymetazoline or xylometazoline hydrochloride
  • oxymetazoline for example oxymetazoline or xylometazoline hydrochloride
  • sprays also include those containing antibiotics, vasoconstrictants, for example oxymetazoline or xylometazoline hydrochloride, which cause swelling of the nasal mucosa, for example in the case of colds, so that it is possible to breathe more freely through the nose.
  • medical devices can be produced that act on a purely physical basis and contain, for example, physiological saline.
  • the nasal sprays according to the invention contain preservatives in order to make the nasal sprays longer-lasting and thus to enable them to be used several times over a longer period of time, such as several weeks or months. This is preferred inasmuch as a repeated application over a longer period is necessary for prevention.
  • the benzalkonium chloride frequently used in the field of nasal drops can be used as a preservative. Surprisingly, however, it has been shown that the seldom used preservatives benzoic acid and sorbic acid lead to a significant increase in durability compared to benzalkonium chloride.
  • the nasal sprays can also be supplemented with their partially or completely neutralized salts.
  • the extract is obtained from a plant of the genus Cistus. From the genus Cistus about 20 species are known:
  • C. incanus also known as C. creticus
  • the extract is preferably obtained from the species C. incanus.
  • C. incanus includes two subspecies, C. incanus ssp. tauricus and C. incanus ssp. undulatus. Of these, the subspecies C. incanus ssp. tauricus used for extraction.
  • the extract is obtained in particular from the above-ground parts of the plants. Preference is given to using the aboveground shoots of the plants which have regrown in the same year.
  • the parts of plants are subjected to extraction immediately after harvesting, that is to say in the raw state. Alternatively, the plant parts are dried before extraction. Subsequently, the leaves of the plant are comminuted in a suitable manner, for example by being rubbed or cut.
  • Suitable solvent centers are aqueous or organic solvents, in particular water, alcohols, such as methanol, ethanol or isopropanol, or chlorinated solvents, such as dichloromethane, and also acetone, acetylacetone, ammonia, carbon dioxide or glacial acetic acid. It is also possible to use mixtures of the solvents mentioned. Preference is given to using a mixture of water with methanol or ethanol.
  • the extraction is usually carried out at room temperature. However, it is also possible to extract at elevated temperatures 25 0 C to perform to the boiling point of the solvent used. Preference is given to extraction at room temperature.
  • the plant material can be extracted several times.
  • different solvents can also be used in the various extraction steps.
  • Aqueous extracts can be diluted or processed undiluted.
  • Organic or organic-aqueous extracts are usually freed from solvents and processed into dry extracts. The dry extracts are then processed into the nasal sprays according to the invention.
  • liquid or dry extracts can be used with the addition of known auxiliaries and additives for the prophylaxis and / or treatment of influenza.
  • the crude product may also be concentrated and / or further worked up before processing into a medicament.
  • the work-up may include, for example, purification steps well known to those skilled in the art, such as centrifugation, filtration and decantation, to remove suspended matter from the extract.
  • the extract described is preferably used for the prophylaxis and / or treatment of influenza, especially cold, flu, influenza infections, such as avian influenza.
  • the ready-made medicaments or medical products in the context of the present invention may in this case contain the customary pharmaceutical auxiliaries, such as preservatives and / or solvents.
  • the extract here may be present at a concentration of from 1 ⁇ g / ml to 100 mg / ml, preferably from 25 ⁇ g / ml to 50 mg / ml.
  • cistus (Cistus) preparations are excellent for both treatment and prophylaxis of upper airway viral infections.
  • the production of a Cistus infusion is carried out by brewing 10 g of cistus herb with 1000 ml of hot water and filtered after 5 min.
  • 100 ml nasal spray contain:
  • 100 ml nasal spray contain:
  • 100 ml nasal spray contain:
  • 100 ml nasal spray contain:
  • 100 ml nasal spray contain:
  • 100 ml nasal spray contain:
  • 100 ml nasal spray contain: 30 g of Cistus infusion 0.9 g of NaCl 70 g of water
  • 100 ml nasal spray contain:
  • 100 ml nasal spray contain:
  • 100 ml nasal spray contain:
  • 100 ml nasal spray contain: 100 g of Cistus infusion 0.9 g NaCl
  • 100 ml nasal spray contain:
  • 100 ml_ nasal spray contain:
  • 100 ml_ nasal spray contain:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne l'utilisation d'un spray nasal comprenant des extraits de ciste pour prévenir et/ou traiter des maladies virales et/ou bactériennes de la cavité buccale et de la gorge.
EP08708284A 2007-02-02 2008-01-28 Extraits de ciste Withdrawn EP2124979A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007006122A DE102007006122A1 (de) 2007-02-02 2007-02-02 Cistusextrakte
PCT/EP2008/050966 WO2008092826A2 (fr) 2007-02-02 2008-01-28 Extraits de ciste

Publications (1)

Publication Number Publication Date
EP2124979A2 true EP2124979A2 (fr) 2009-12-02

Family

ID=39587358

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08708284A Withdrawn EP2124979A2 (fr) 2007-02-02 2008-01-28 Extraits de ciste

Country Status (6)

Country Link
US (2) US20100062068A1 (fr)
EP (1) EP2124979A2 (fr)
JP (1) JP2010517956A (fr)
CN (1) CN101626776A (fr)
DE (1) DE102007006122A1 (fr)
WO (1) WO2008092826A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007006122A1 (de) 2007-02-02 2008-08-07 Krewel Meuselbach Gmbh Cistusextrakte
IT202100018035A1 (it) 2021-07-08 2023-01-08 St Farmochimico Fitoterapico Epo S R L Ed In Forma Abbreviata Epo S R L ASSOCIAZIONE ANTIBATTERICA SINERGICA DI ESTRATTI DI SCUTELLARIA LATERIFLORA E DI CISTUS x INCANUS
WO2024046653A1 (fr) 2022-08-29 2024-03-07 Mycotech Pharma As Extraits fongiques antiviraux

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508282C1 (en) * 1993-05-17 2001-01-23 Tulin Silver Jeffrey Composition and method for treating acute or chronic rhinosinusitis
JP4097737B2 (ja) * 1997-04-07 2008-06-11 ユニチカ株式会社 鼻口腔用抗炎症散布剤
JPH11322582A (ja) * 1998-05-06 1999-11-24 Dot:Kk 経鼻吸収用鼻粘膜付着・滞留型キャリヤ
ATE226429T1 (de) * 1998-08-24 2002-11-15 Procter & Gamble Orale flüssige mucoadhäsive zusammensetzungen
JP2000217916A (ja) * 1999-01-01 2000-08-08 Masakazu Imai 人力・電力両用で作動する粒子選択性ネブライザ―とその製造法
PL199782B1 (pl) * 1999-10-19 2008-10-31 Procter & Gamble Środek do nosa do zapobiegania i leczenia wirusowego przeziębienia i grypy
US6664289B2 (en) * 2002-03-18 2003-12-16 Richard L. Hansen Nasal solution containing a broad spectrum microbicide and a method for its use
CA2489528A1 (fr) * 2002-06-20 2003-12-31 Novartis Consumer Health S.A. Compositions nasales contenant un glycosaminoglycane et un propylene glycol
WO2004019960A2 (fr) * 2002-08-28 2004-03-11 Lupin Ltd. Extrait de plantes contenant un melange de saponines obtenues a partir du sapindus trifoliatus a activite anti-convulsivante
AT413078B (de) * 2002-10-10 2005-11-15 Gebro Pharma Gmbh Verwendung eines puffers auf basis von apfelsäure für die herstellung einer nasal applizierbaren zubereitung
CA2583101A1 (fr) * 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions et methodes d'administration par voie pulmonaire, sublinguale, orale et intranasale de varenicline
EP2286823B1 (fr) * 2005-09-13 2015-06-17 Georgios Pandalis Extraits de plantes du genre Cistus pour utilisation dans la prévention ou le traitement de la grippe
DE202005014459U1 (de) 2005-09-13 2006-01-19 Pandalis, Georgios, Dr. Aerosol zur Vorbeugung und Behandlung der Influenza
ES2314772T3 (es) * 2006-03-24 2009-03-16 Georgios Pandalis Composicion para la prevencion y tratamiento de afecciones catarrales.
CN101405015B (zh) * 2006-03-24 2015-04-01 乔治斯·潘达利斯 用于预防和治疗普通感冒病的组合物
DE102007006122A1 (de) 2007-02-02 2008-08-07 Krewel Meuselbach Gmbh Cistusextrakte

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008092826A2 *

Also Published As

Publication number Publication date
US20100062068A1 (en) 2010-03-11
US20120201866A1 (en) 2012-08-09
JP2010517956A (ja) 2010-05-27
US8691294B2 (en) 2014-04-08
WO2008092826A3 (fr) 2009-03-05
DE102007006122A1 (de) 2008-08-07
WO2008092826A2 (fr) 2008-08-07
CN101626776A (zh) 2010-01-13

Similar Documents

Publication Publication Date Title
DE60119534T2 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
EP2367557B1 (fr) Composition pour le traitement de maladies infectieuses de la cavité buccale et pharyngienne
DE60113291T2 (de) Präparate zur behandlung von allergischen symptomen und deren herstellungsverfahren
WO2008092826A2 (fr) Extraits de ciste
DE202006011920U1 (de) Zusammensetzung zur Behandlung von Rhinitis
EP3285791B1 (fr) Composition pour le traitement de la cavité laryngopharyngée
EP0668768B1 (fr) Composition permettant de lutter contre les dermatomycoses et leurs agents causals, ainsi que contre la sudation et les odeurs corporelles
EP3407890B1 (fr) Préparation pharmaceutique et son utilisation pour le traitement de la laryngite virale
EP3352763B1 (fr) Substance pour la prophylaxie et le traitement d'infections provoquées par des virus influenza
WO2010025577A2 (fr) Préparation destinée à la prévention et/ou au traitement et/ou à la limitation de la propagation de maladies des voies respiratoires
DE202005014459U1 (de) Aerosol zur Vorbeugung und Behandlung der Influenza
DE202006005924U1 (de) Zusammensetzung zur Behandlung von Rhinitis
EP1684775A1 (fr) Utilisation d'extraits de l'espece pelargonium
EP3285790A1 (fr) Composition pour le traitement de la cavité laryngopharyngée
EP4103212A1 (fr) Composition
EP2268294B1 (fr) Extrait de propolis
DE202019005007U1 (de) Kamillenfluidextrakt
DE202005014460U1 (de) Tablette zur Vorbeugung und Behandlung der Influenza
CH699653A1 (de) Zubereitung zur Prävention und/oder Behandlung und/oder Verhinderung der Weiterverbreitung von Atemwegserkrankungen.
DE102020007979A1 (de) Zusammensetzung zur Behandlung von lnfektionen mit Coronaviren
DE202015104316U1 (de) Zusammensetzung für die Behandlung des Hals-/Rachenraums
WO2005058338A1 (fr) Utilisation d'un extrait d'aloysia/verbena/lippia triphylla/citriodora pour traiter des affections chroniques et/ou inflammatoires
WO2018185348A1 (fr) Composition pharmaceutique pour traiter des intoxications aigües
DE202015104329U1 (de) Zusammensetzung für die Behandlung des Hals-/Rachenraums
DE202005020574U1 (de) Medikament zur Vorbeugung und Behandlung der Influenza

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090710

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130627

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140308